News

Ophthalmology Advisor9h
High Dose Aflibercept Gets Priority Review for Retinal Vein Occlusion and Monthly Dosing
The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.
Ophthalmology Times14h
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR
The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...
Fierce Pharma14h
Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer
After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...
Durham Herald Sun5d
Fujifilm lands another drugmaker to new Holly Springs plant with $3 billion deal
On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...
Regeneron receives complete response letter for Eylea extended dosing
Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the ...
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...
Biocon Biologics Ltd.: Biocon Biologics Secures Market Entry Date for Yesafili, an Interchangeable Biosimilar to Eylea, in the U.S.
BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...
Le Lézard13d
Biocon Biologics Secures Market Entry Date for Yesafilitm, an Interchangeable Biosimilar to Eylea®, in the U.S.
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...
Biocon shares jump 4 per cent after subsidiary secures US market entry for Yesafili
BENGALURU: Biopharmaceutical company Biocon's share price on Tuesday jumped over 4 per cent after its subsidiary Biocon ...
BioSpace15d
FDA Action Alert: Regeneron, Sanofi and Abeona
Regeneron Proposes Longer Dosing Interval for Eylea HD In a bid to maintain the market dominance of its blockbuster biologic Eylea, Regeneron is working to improve the product profile of the high-dose ...
Nasdaq18d
May 30th Options Now Available For Regeneron Pharmaceuticals
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
as.com18d
These are the drugs that lose their U.S. patents in 2025: most are in common use across the country by millions of people
Generic competition is already on the horizon, with Sandoz emerging as a key player. Regeneron’s Eylea, prescribed for age-related macular degeneration and diabetic eye conditions, is another ...